HOME >> BIOLOGY >> NEWS
New therapeutic insight into duchenne muscular dystrophy

In the April 1st issue of Genes & Development, Dr. Bruce Spiegelman (Dana Farber Cancer Institute) and colleagues identify a key genetic component of and possible therapeutic target for Duchenne muscular dystrophy.

Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy, affecting about 1 in 3000 males each year. It is an X-linked recessive disease, in which mutations in the dystrophin gene causes progressive and degenerative muscle weakness. DMD is generally lethal by age 30.

Dr. Spiegelman and colleagues found that a protein called PGC-1alpha regulates the point of connection between the end of a motor neuron and a muscle fiber what researchers call the "neuromuscular junction." Electrical impulses travel through the neuromuscular junction, ultimately causing the muscle to contract. Previous research has shown that PGC-1alpha expression is induced by physical exercise and motor neuron activity, and mediates the anti-atrophic effects of nerve activity on muscle mass.

Dr. Spiegelman and colleagues analyzed the function of PGC-1alpha in a mouse model of DMD. They found that PGC-1alpha activates the expression of several genes that are aberrantly inactivated in DMD. In fact, by inducing PGC-1alpha expression in these transgenic mice, the scientists were able to improve DMD symptoms.

"These data clearly show that experimental elevation of PGC-1 alpha has therapeutic promise in an animal model of Duchene's muscular dystrophy. We hope this will lead eventually to therapeutics for a terrible disease for which there is no effective treatment at the present time," explains Dr. Spiegelman.


'"/>

Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory
31-Mar-2007


Page: 1

Related biology news :

1. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
2. From clinical cancer research: rethinking therapeutic cancer vaccine trials
3. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
4. Small molecule derived from Rb2/p130 could act as cancer therapeutic
5. Sphingolipids with therapeutic ends
6. New therapeutic target for Alzheimers could lead to drugs without side effects
7. VBI research offers potential route to diabetes therapeutics
8. Quiet revolution may herald new RNA therapeutics
9. Scientists discover two-component lantibiotic with therapeutic potential
10. Potential new therapeutic target for asthma, allergies and cancer
11. Chemical genomic screening identifies novel therapeutic strategies for cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/14/2019)... ... May 13, 2019 , ... ... 4th, at a very special Pre-EWMA 2019 event at Gothenburg’s Universeum Aquarium. Guests ... Trends, Opportunities and Innovations in Advanced Wound Care. , SmartTRAK’s Advanced Wound Care ...
(Date:5/8/2019)... ... May 07, 2019 , ... Modality ... invitation-only community for world-class CIOs, CTOs, and technology executives. Modality Solutions ... firm that guarantees confidence in a company’s cold chain. Subject-matter experts provide ...
(Date:5/8/2019)... Conn. and TORONTO (PRWEB) , ... May 08, ... ... growth recapitalization of Axiom Real-Time Metrics (“Axiom”), a premier provider of unified eClinical ... II and III clinical trials and observational studies. Axiom is a leading e-clinical ...
Breaking Biology News(10 mins):
(Date:5/7/2019)... VANCOUVER, British Columbia (PRWEB) , ... May 06, ... ... will be a go-to resource for the growing number of repositories being asked ... We are grateful to the team of contributors who are world leaders, ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... ISO 9001:2015 standard, REPROCELL USA Inc. has demonstrated its ability to provide ... USA Inc. aims to enhance customer satisfaction through the effective implementation of ...
(Date:5/2/2019)... ... May 02, 2019 , ... ... company, will present results documenting discrepancies between U.S. insurer policies for genetic testing ... at risk for hereditary breast and ovarian cancer (HBOC). , Jill ...
(Date:4/25/2019)... ... April 24, 2019 , ... ... for sales and service organizations, today announced global availability of Inference Studio’s latest ... enterprises of all sizes to harness the power of Google’s Contact Center ...
Breaking Biology Technology:
Cached News: